EAGLE PHARMACEUTICALS, INC. Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K/A)

Item 7.01 Regulation FD Disclosure.

On January 10, 2023, the Company made available the attached Updated Presentation of the Company's business, products and product candidates, which the Company will use at its previously announced presentation at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, California, being held January 9-12, 2023, and from time to time in meetings with investors.

The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, regardless of any general incorporation language in such filing.

Item 9.01 Financial Statements and Exhibits.

Exhibit No.   Description
   99.1         Updated Presentation of the Company
    104       Cover Page Interactive Data File (embedded within the Inline XBRL
              document).

© Edgar Online, source Glimpses